Edition:
United Kingdom

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

58.40USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$58.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
156,927
52-wk High
$62.75
52-wk Low
$10.05

Chart for

About

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008,... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $1,207.95
Shares Outstanding(Mil.): 31.54
Dividend: --
Yield (%): --

Financials

  ZGNX.OQ Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -3.38 -- --
ROI: -39.41 2.22 14.61
ROE: -70.89 3.86 16.34

Zogenix's seizure drug clears late-stage trial, shares soar

Zogenix Inc said on Thursday its drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer's shares up as much as 26 percent.

12 Jul 2018

UPDATE 2-Zogenix's seizure drug clears late-stage trial, shares soar

July 12 Zogenix Inc said on Thursday its drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer's shares up as much as 26 percent.

12 Jul 2018

Zogenix's treatment for rare epilepsy meets advanced study goal

July 12 Zogenix Inc said on Thursday its drug to treat Dravet syndrome, a rare form of epilepsy, met the main goal of a late-stage trial.

12 Jul 2018

BRIEF-Zogenix Q1 Loss Per Share $0.87

* ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER FINANCIAL RESULTS

09 May 2018

BRIEF-Zogenix Inc Q4 Loss Per Share $1.17

* ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

06 Mar 2018

BRIEF-Zogenix Completes Enrollment In Second ZX008 Phase 3 Clinical Trial In Dravet Syndrome

* ZOGENIX COMPLETES ENROLLMENT IN SECOND ZX008 PHASE 3 CLINICAL TRIAL IN DRAVET SYNDROME

31 Jan 2018

Earnings vs. Estimates